Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in microglia (321 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 81 | 0.91 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
Knock down and overexpress RHBDF2 in microglia; measure IL-1β and TNF release and surface HLA-DR and uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release).
- Cell type
- microglia
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release)
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of RHBDF2 in iPSC-derived microglia (iMGL); n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; uptake and clearance of α-synuclein fibrils and NLRP3 inflammasome activation (IL-1β release). Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- RHBDF2 in dopamine neurons, braak-0.41 (p 0.269) → -0.58 (p 0.102)receipt 4109
- RHBDF2 in microglia, braak-0.41 (p 0.273) → -0.04 (p 0.912)receipt 4108
Swarm cases
receipt 4109: RHBDF2 in dopamine neurons, braak
- power
- full sample -0.47 (p 0.051, n 18), 95% CI -0.77 to +0.00. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.44 (p 0.070, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.035, n 18). not the mix.
- skeptic
- leave-one-out range -0.57 to -0.41, sign flips 0; without severely affected donors -0.47 (p 0.051, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RHBDF2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 4108: RHBDF2 in microglia, braak
- power
- full sample -0.34 (p 0.173, n 18), 95% CI -0.69 to +0.16. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.36 (p 0.140, n 18). does not hold up.
- composition
- microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.36 (p 0.140, n 18). could be the mix.
- skeptic
- leave-one-out range -0.53 to -0.25, sign flips 0; without severely affected donors -0.34 (p 0.173, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RHBDF2 in microglia.
case closed: nothing better to follow up.
Receipts
loading the receipts